# Salvage Therapy With High Dose Oral Clarithromycin in Relapsed or Refractory Extranodal Marginal Zone Lymphoma

> **NCT01516606** · PHASE2 · COMPLETED · sponsor: **Andres J. M. Ferreri** · enrollment: 23 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** clarithromycin, oral, high dose

## Key facts

- **NCT ID:** NCT01516606
- **Lead sponsor:** Andres J. M. Ferreri
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2013-12
- **Final completion:** 2014-12
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2022-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01516606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01516606, "Salvage Therapy With High Dose Oral Clarithromycin in Relapsed or Refractory Extranodal Marginal Zone Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01516606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*